{
    "clinical_study": {
        "@rank": "159913", 
        "arm_group": [
            {
                "arm_group_label": "APF530 500 mg SC", 
                "arm_group_type": "Experimental", 
                "description": "APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC"
            }, 
            {
                "arm_group_label": "ondansetron 0.15 mg/kg IV", 
                "arm_group_type": "Active Comparator", 
                "description": "Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary study objective is to demonstrate the superiority of APF530 500 mg given\n      subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a\n      maximum of 16 mg) in the delayed-phase (> 24-120 hours) complete response (CR) rate (defined\n      as no emesis and no use of rescue medications) in subjects receiving highly emetogenic\n      chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines"
        }, 
        "brief_title": "A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chemotherapy-induced Nausea and Vomiting", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects will be males or nonpregnant females who are 18-75 years of age at the time\n             of enrollment.\n\n          -  Subjects must have histologically or cytologically confirmed malignant disease.\n\n          -  Subjects must be undergoing treatment with a HEC regimen according to the 2011 ASCO\n             CINV guidelines for further details on the emetogenic classifications of chemotherapy\n             agents for this study).\n\n          -  A life expectancy > 6 months\n\n          -  Subjects must be able to receive standardized doses of dexamethasone as   required in\n             the protocol for the prevention of emesis.\n\n          -  Subjects must be characterized as having Eastern Cooperative Oncology Group (ECOG)\n             performance status of 0 or 1.\n\n          -  Subjects must have adequate bone marrow, kidney, and liver function.\n\n          -  Subjects must be able to swallow oral medications (pills) without difficulty.\n\n          -  Subjects must be entering the first cycle of their current chemotherapy regimen.\n\n          -  Subjects must be willing and able to comply with all testing and requirements defined\n             in the protocol.\n\n          -  Subjects must be able to provide voluntary, written, informed consent to participate\n             in this study and must be able to fully understand the study requirements.\n\n          -  Female subjects cannot be pregnant and must be adequately protected from conception\n             for the duration of study, using at least one form of contraception. It is\n             recommended that females and female partners of male subjects remain adequately\n             protected from conception during the study and for up to 1 year following study\n             participation.\n\n        Exclusion Criteria:\n\n          -  Subject has a known hypersensitivity to granisetron or any 5-HT3 receptor antagonist.\n\n          -  Subject has a history or presence of clinically significant abnormal 12-lead ECG or\n             an ECG with QTc by Bazett's correction of > 450 msec in men and > 470 msec in women\n             on the screening ECG.\n\n          -  Subject has PR > 240 msec, QRS > 110 msec, or a history of prolongation of QT\n             interval.\n\n          -  Subject has a family history of long QT syndrome.\n\n          -  Subject has a history of cardiac disease, including congenital long QT syndrome,\n             angina, myocardial ischemia or infarction, congestive heart failure, myocarditis, or\n             chest pain or dyspnea on exertion.\n\n          -  Subject has an electrolyte disturbance, such as uncorrected hypokalemia/hyperkalemia,\n             hypomagnesemia, or hypocalcemia.\n\n          -  Subject has idiopathic cardiomyopathy, syncope, epilepsy, hypertrophic\n             cardiomyopathy, or other clinically significant cardiac disease.\n\n          -  Subject is pregnant or breast-feeding.\n\n          -  Subject is planning to receive multiple-day chemotherapy.\n\n          -  Subject has taken any of the following agents within 7 days prior to initiation of\n             chemotherapy (the study): 5-HT3 receptor antagonists, phenothiazines, benzamides,\n             domperidone, cannabinoids, or NK-1 receptor antagonist.\n\n          -  Subject has taken any benzodiazepine within 1 day (24 hours) prior to initiation of\n             chemotherapy (the study).\n\n          -  Subject is scheduled to receive any other chemotherapeutic agent from Day 2 through\n             Day 6.\n\n          -  Subject is scheduled to receive any radiation therapy to the abdomen or pelvis from\n             Day -5 through Day 6.\n\n          -  Subject has received systemic corticosteroids or sedative antihistamines within 72\n             hours of Day 1 of the study, except as premedication for chemotherapy (e.g., taxanes,\n             pemetrexed).\n\n          -  Subject has symptomatic primary or metastatic central nervous system (CNS) disease.\n\n          -  Subject has ongoing vomiting, retching, or nausea caused by any etiology, or has a\n             history of anticipatory nausea and vomiting.\n\n          -  Subject has vomited and/or has had dry heaves or retching within 24 hours prior to\n             the start of HEC on Day 1.\n\n          -  Subject is NOT able to swallow oral medications (pills) without difficulty."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106494", 
            "org_study_id": "C2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "APF530 500 mg SC", 
                    "ondansetron 0.15 mg/kg IV"
                ], 
                "intervention_name": "Dexamethasone 12 mg IV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "APF530 500 mg SC", 
                    "ondansetron 0.15 mg/kg IV"
                ], 
                "intervention_name": "fosaprepitant 150 mg IV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Ondansetron", 
                "Granisetron", 
                "Aprepitant", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Highly emetogenic chemotherapy (HEC)", 
            "Chemotherapy-Induced Nausea and Vomiting (CINV)"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Canton", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44718"
                }, 
                "name": "Gabrail Cancer center Research"
            }, 
            "investigator": {
                "last_name": "Nashat Y Gabrail, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy", 
        "overall_contact": {
            "email": "mgelder@herontx.com", 
            "last_name": "Mark Gelder, MD"
        }, 
        "overall_official": {
            "affiliation": "Heron Therapeutics", 
            "last_name": "Mark Gelder, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120 hours) complete response (CR) rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines in Cycle 1.", 
            "measure": "Complete response rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy.", 
            "safety_issue": "No", 
            "time_frame": "Cycle 1; Day 1 through 5 after adminstration of chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Heron Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Heron Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}